Skip to Content

Cresemba Approval History

FDA Approved: Yes (First approved March 6, 2015)
Brand name: Cresemba
Generic name: isavuconazonium
Dosage form: Capsules and Injection
Company: Astellas Pharma US, Inc.
Treatment for: Invasive Aspergillosis; Invasive Mucormycosis

Cresemba (isavuconazonium) is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Development History and FDA Approval Process for Cresemba

DateArticle
Mar  6, 2015Approval FDA Approves Cresemba (isavuconazonium sulfate) For Fungal Infections
Jan 22, 2015Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of Cresemba (isavuconazonium)
Nov  3, 2014Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis
Jul  9, 2014Astellas Submits NDA for Isavuconazole Invasive Aspergillosis and Invasive Mucormycosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide